HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

CanSino Biologics (6185.HK/688185.CH) - Time to Offload; the Rally May Not Last Long

China Healthcare Weekly (Nov4)-Opportunity in Culture Medium, European API, Long Logic of Investment

2023 High Conviction - China Healthcare: Recognize the Direction and Follow the Trend

Bloomage Biotechnology (688363.CH) - Positioning and Strategic Layout Imply Strong Upside Potential

CanSino Biologics (688185.CH/6185.HK) -Difficulties in 2022 Cannot Mask Long-Term Investment Value

CanSino Biologics (6185.HK/688185.CH) - Still Have Investment Value

Gravity Works As WeWork Doesn't; Now Plan B

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cansino-biologics-inc-cc0c90b7-e854-4ba3-929b-914be1bd0d89" target="_blank" data-smartkarma-citation="entities:32181:1" rel="noopener">CanSino Biologics Inc (688185 CH)'</a>s business has made some positive progress recently, including the launch of COVID-19 Vaccine for Inhalation, commercialization and development progress of MCV4/PCV13i, etc. </li>
<li>CanSino's technology platforms are very valuable and are above average level. Currently, there’re little potential domestic competitors, because CanSino’s products are newer, better and safer than domestic homogenized products.</li>
<li>Even based on conservative forecast, CanSino’s valuation in HKEX is “ridiculously low”. Considering the downside risk in HKEX, CanSino A-share could be better option before valuation in HKEX becomes reasonable.</li>
</ul>



CanSino Biologics Inc (688185 CH)'s business has made some positive progress recently, including the launch of COVID-19 Vaccine for Inhalation, commercialization and development progress of MCV4/PCV13i, etc. 
CanSino's technology platforms are very valuable and are above average level. Currently, there’re little potential domestic competitors, because CanSino’s products are newer, better and safer than domestic homogenized products.
Even based on conservative forecast, CanSino’s valuation in HKEX is “ridiculously low”. Considering the downside risk in HKEX, CanSino A-share could be better option before valuation in HKEX becomes reasonable.


Chongqing Zhifei Biological Products (300122 CH)

Shenzhen Kangtai Biological Pr (300601 CH)

CanSino Biologics Inc (688185.CH/6185.HK) - Some Positive Progress in Business